{"id":3485,"date":"2026-09-25T16:30:00","date_gmt":"2026-09-25T20:30:00","guid":{"rendered":"https:\/\/www.insilens.com\/?p=3485"},"modified":"2026-09-28T22:01:15","modified_gmt":"2026-09-29T02:01:15","slug":"ifinatamab-deruxtecan-accelerated-filing-withdrawn","status":"publish","type":"post","link":"https:\/\/www.insilens.com\/?p=3485","title":{"rendered":"Ifinatamab Deruxtecan Accelerated Filing Withdrawn"},"content":{"rendered":"

\"\"<\/p>\n

Company<\/strong><\/p>\n

Daiichi Sankyo; Merck<\/p>\n

Event Type<\/strong><\/p>\n

Accelerated Approval Application Withdrawn<\/p>\n

Modality<\/strong><\/p>\n

Antibody-Drug Conjugate<\/p>\n

Asset<\/strong><\/p>\n

Ifinatamab Deruxtecan<\/p>\n

Target<\/strong><\/p>\n

B7-H3<\/p>\n

Disease Area<\/strong><\/p>\n

Extensive-Stage Small-Cell Lung Cancer<\/p>\n

Summary<\/h4>\n

Daiichi Sankyo and Merck voluntarily withdrew the U.S. accelerated-approval application for ifinatamab deruxtecan in previously treated extensive-stage small-cell lung cancer after FDA discussions concluded that the supporting data, including Phase 2 IDeate-Lung01, did not satisfy the requirements for the proposed indication. The decision removes an October 10 PDUFA catalyst. Enrollment continues in the randomized Phase 3 IDeate-Lung02 trial. This is a negative regulatory signal for the near-term SCLC path, but it does not establish lack of drug activity or terminate the broader B7-H3 ADC program.<\/p>\n

The application had Priority Review, Breakthrough Therapy designation, Real-Time Oncology Review participation and Project Orbis review. It relied on a single-arm Phase 2 dataset in which the companies previously reported a blinded-review response rate of 48.2% in 137 patients at the selected dose. FDA nevertheless determined that the total package did not support accelerated approval for the proposed post-platinum indication.<\/p>\n

The companies did not disclose a new safety finding, manufacturing problem or single causal deficiency. IDeate-Lung02 continues to compare ifinatamab deruxtecan with physician\u2019s-choice chemotherapy after one prior platinum line, with enrollment near completion. Separate Phase 3 studies continue in prostate and esophageal cancers.<\/p>\n

Deep Analysis<\/h4>\n

Accelerated approval requires a surrogate endpoint reasonably likely to predict benefit plus an acceptable totality of evidence. A substantial response rate can still be insufficient if durability, population definition, benefit-risk, endpoint reliability or confirmatory feasibility do not meet the standard. Because FDA\u2019s specific concerns are undisclosed, attributing the withdrawal to efficacy, safety or manufacturing alone would be speculation.<\/p>\n

The randomized Phase 3 trial becomes the decisive SCLC asset, delaying potential entry and increasing dependence on comparative outcomes. Continued trials in other tumors preserve platform optionality, but the withdrawal raises the evidence threshold for a B7-H3 class in which no therapy is yet approved.<\/p>\n

Two interpretations remain plausible. The negative interpretation is that the Phase 2 profile lacked sufficient magnitude or durability to justify early market access. The less negative interpretation is that FDA is applying a stricter accelerated-approval standard and wants randomized confirmation despite genuine activity. Phase 3 PFS, OS, response durability and interstitial-lung-disease data will distinguish these views; failure to beat active chemotherapy would materially falsify the SCLC thesis.<\/p>\n

Company and Product Background<\/h4>\n

Daiichi Sankyo discovered ifinatamab deruxtecan and jointly develops it with Merck outside Japan. The ADC combines a humanized B7-H3 antibody with a cleavable linker and an exatecan-derived topoisomerase-I payload. B7-H3 is highly expressed in small-cell lung cancer and other tumors but also has normal-tissue distribution relevant to safety. Extensive-stage SCLC is aggressive, and post-platinum options have limited durability.<\/p>\n

Signal Extraction<\/h4>\n
    \n
  • Regulatory signal: the accelerated BLA was voluntarily withdrawn after FDA concluded the package was insufficient.<\/li>\n
  • Timing signal: the October 10 PDUFA event is removed.<\/li>\n
  • Clinical continuity: randomized Phase 3 enrollment continues and is near completion.<\/li>\n
  • Unresolved cause: no specific safety, manufacturing or efficacy deficiency was disclosed.<\/li>\n
  • Decisive next evidence: comparative Phase 3 survival, durability and pulmonary-safety results.<\/li>\n<\/ul>\n

    InSilens Take<\/h4>\n

    This is a high-importance negative signal because it converts a near-term first-in-class approval opportunity into a Phase 3 wait. The proper conclusion is narrower than a clinical failure: the existing package was insufficient for accelerated approval. Merck and Daiichi Sankyo retain a plausible path through randomized evidence, but the burden has shifted from response-rate enthusiasm to comparative benefit and mature safety.<\/p>\n

    Signal Assessment<\/h4>\n

    Signal Importance: 5 of 5. Signal Direction: negative for the near-term U.S. indication. Confidence in Facts: high. Confidence in Interpretation: moderate because FDA\u2019s detailed deficiency analysis is not public. Red-team conclusion: withdrawal is not proof of no activity, and continued Phase 3 development is meaningful contradictory evidence.<\/p>\n","protected":false},"excerpt":{"rendered":"

    Daiichi Sankyo and Merck voluntarily withdrew the U.S. accelerated-approval application for ifinatamab deruxtecan in previously treated extensive-stage small-cell lung cancer after FDA discussions concluded that the supporting data, including Phase 2 IDeate-Lung01, did not…<\/p>\n","protected":false},"author":1,"featured_media":3493,"comment_status":"open","ping_status":"open","sticky":false,"template":"","format":"standard","meta":{"footnotes":""},"categories":[3],"tags":[752,883,123,882],"class_list":["post-3485","post","type-post","status-publish","format-standard","has-post-thumbnail","hentry","category-therapeutic-indication","tag-daiichi-sankyo","tag-ifinatamab-deruxtecan","tag-merck","tag-small-cell-lung-cancer"],"blocksy_meta":[],"_links":{"self":[{"href":"https:\/\/www.insilens.com\/index.php?rest_route=\/wp\/v2\/posts\/3485","targetHints":{"allow":["GET"]}}],"collection":[{"href":"https:\/\/www.insilens.com\/index.php?rest_route=\/wp\/v2\/posts"}],"about":[{"href":"https:\/\/www.insilens.com\/index.php?rest_route=\/wp\/v2\/types\/post"}],"author":[{"embeddable":true,"href":"https:\/\/www.insilens.com\/index.php?rest_route=\/wp\/v2\/users\/1"}],"replies":[{"embeddable":true,"href":"https:\/\/www.insilens.com\/index.php?rest_route=%2Fwp%2Fv2%2Fcomments&post=3485"}],"version-history":[{"count":2,"href":"https:\/\/www.insilens.com\/index.php?rest_route=\/wp\/v2\/posts\/3485\/revisions"}],"predecessor-version":[{"id":3504,"href":"https:\/\/www.insilens.com\/index.php?rest_route=\/wp\/v2\/posts\/3485\/revisions\/3504"}],"wp:featuredmedia":[{"embeddable":true,"href":"https:\/\/www.insilens.com\/index.php?rest_route=\/wp\/v2\/media\/3493"}],"wp:attachment":[{"href":"https:\/\/www.insilens.com\/index.php?rest_route=%2Fwp%2Fv2%2Fmedia&parent=3485"}],"wp:term":[{"taxonomy":"category","embeddable":true,"href":"https:\/\/www.insilens.com\/index.php?rest_route=%2Fwp%2Fv2%2Fcategories&post=3485"},{"taxonomy":"post_tag","embeddable":true,"href":"https:\/\/www.insilens.com\/index.php?rest_route=%2Fwp%2Fv2%2Ftags&post=3485"}],"curies":[{"name":"wp","href":"https:\/\/api.w.org\/{rel}","templated":true}]}}